NNNN logo

Anbio BiotechnologyNasdaqGM:NNNN Stock Report

Market Cap US$248.9m
Share Price
n/a
1Yn/a
7Dn/a
Portfolio Value
View

Anbio Biotechnology

NasdaqGM:NNNN Stock Report

Market Cap: US$248.9m

NNNN Stock Overview

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. More details

NNNN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Anbio Biotechnology Competitors

Price History & Performance

Summary of share price highs, lows and changes for Anbio Biotechnology
Historical stock prices
Current Share PriceUS$5.67
52 Week HighUS$5.89
52 Week LowUS$5.18
Beta0
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-1.73%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

NNNNUS BiotechsUS Market
7Dn/a2.2%-2.2%
1Yn/a-1.9%18.3%

Return vs Industry: Insufficient data to determine how NNNN performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NNNN performed against the US Market.

Price Volatility

Is NNNN's price volatile compared to industry and market?
NNNN volatility
NNNN Average Weekly Movementn/a
Biotechs Industry Average Movement10.9%
Market Average Movement6.0%
10% most volatile stocks in US Market17.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: NNNN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NNNN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2021n/aMichael Lauwww.anbio.com

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets.

Anbio Biotechnology Fundamentals Summary

How do Anbio Biotechnology's earnings and revenue compare to its market cap?
NNNN fundamental statistics
Market capUS$248.86m
Earnings (TTM)US$4.33m
Revenue (TTM)US$9.50m

57.5x

P/E Ratio

26.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NNNN income statement (TTM)
RevenueUS$9.50m
Cost of RevenueUS$4.03m
Gross ProfitUS$5.47m
Other ExpensesUS$1.14m
EarningsUS$4.33m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.099
Gross Margin57.61%
Net Profit Margin45.57%
Debt/Equity Ratio0%

How did NNNN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 01:38
End of Day Share Price 2025/02/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anbio Biotechnology is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.